Literature DB >> 23531874

A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal.

Filip Janku1, Helen J Huang, Laura S Angelo, Razelle Kurzrock.   

Abstract

It has been demonstrated that epidermal growth factor receptor (EGFR) can have kinase independent activity. EGFR kinase-independent function maintains intracellular glucose levels via sodium glucose transporter protein 1 (SGLT1) and supports cell survival. It is plausible that this phenomenon can apply to other receptor tyrosine kinases. We found that transfection of insulin-like growth factor receptor (IGF-1R) siRNA into HEK293 (human embryonic kidney) and MCF7 (metastatic breast cancer) cells result in decreased intracellular glucose levels, whereas treatment with an IGF-1R tyrosine kinase inhibitor OSI-906 did not affect intracellular glucose levels. In addition, IGF-1R interacted with SGLT1 in a manner similar to that previously reported with EGFR. The combination of IGF-1R siRNA and OSI-906 resulted in decreased viability of HEK293 and MCF7 cell lines compared to either agent alone. Collectively, these experiments suggest that IGF-1R, has kinase-independent biologic functions and provide a rationale for combining anti-IGF-1R antibodies or siRNA and IGF-1R small molecule inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23531874      PMCID: PMC3717308          DOI: 10.18632/oncotarget.886

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  39 in total

1.  Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.

Authors:  Aung Naing; Razelle Kurzrock; Angelika Burger; Sachin Gupta; Xiudong Lei; Naifa Busaidy; David Hong; Helen X Chen; Lawrence A Doyle; Lance K Heilbrun; Eric Rohren; Chaan Ng; Chandtip Chandhasin; Patricia LoRusso
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

2.  Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.

Authors:  Bolin Liu; Zeying Fan; Susan M Edgerton; XiaoHe Yang; Stuart E Lind; Ann D Thor
Journal:  Cell Cycle       Date:  2011-09-01       Impact factor: 4.534

3.  Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.

Authors:  Deniz A Ucar; Elena Kurenova; Timothy J Garrett; William G Cance; Carl Nyberg; Audrey Cox; Nicole Massoll; David A Ostrov; Nicholas Lawrence; Said M Sebti; Maria Zajac-Kaye; Steven N Hochwald
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

4.  Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.

Authors:  Xianke Zeng; Hua Zhang; Annabell Oh; Yan Zhang; Douglas Yee
Journal:  Breast Cancer Res Treat       Date:  2011-08-18       Impact factor: 4.872

Review 5.  Insulin-like growth factor receptor inhibitors: baby or the bathwater?

Authors:  Douglas Yee
Journal:  J Natl Cancer Inst       Date:  2012-07-03       Impact factor: 13.506

6.  Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Authors:  Y Wu; M M Amonkar; B H Sherrill; J O'Shaughnessy; C Ellis; J Baselga; K L Blackwell; H J Burstein
Journal:  Ann Oncol       Date:  2011-03-15       Impact factor: 32.976

7.  Induction of autophagy and inhibition of tumorigenesis by beclin 1.

Authors:  X H Liang; S Jackson; M Seaman; K Brown; B Kempkes; H Hibshoosh; B Levine
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

Review 8.  Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.

Authors:  I Stuart Wood; Paul Trayhurn
Journal:  Br J Nutr       Date:  2003-01       Impact factor: 3.718

9.  A MEK-independent role for CRAF in mitosis and tumor progression.

Authors:  Ainhoa Mielgo; Laetitia Seguin; Miller Huang; Maria Fernanda Camargo; Sudarshan Anand; Aleksandra Franovic; Sara M Weis; Sunil J Advani; Eric A Murphy; David A Cheresh
Journal:  Nat Med       Date:  2011-11-13       Impact factor: 53.440

10.  The interfaces between signal transduction pathways: IGF-1/mTor, p53 and the Parkinson Disease pathway.

Authors:  Arnold J Levine; Chris R Harris; Anna M Puzio-Kuter
Journal:  Oncotarget       Date:  2012-11
View more
  15 in total

1.  Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.

Authors:  Gerald S Falchook; Jennifer J Wheler; Aung Naing; Sarina A Piha-Paul; Siqing Fu; Apostolia M Tsimberidou; David S Hong; Filip Janku; Ralph Zinner; Yunfang Jiang; Mei Huang; Quan Lin; Kristin Parkhurst; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2014-11-04       Impact factor: 3.850

Review 2.  The role of FAK in tumor metabolism and therapy.

Authors:  Jianliang Zhang; Steven N Hochwald
Journal:  Pharmacol Ther       Date:  2013-12-09       Impact factor: 12.310

3.  A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.

Authors:  Gerald S Falchook; Stacy Moulder; Aung Naing; Jennifer J Wheler; David S Hong; Sarina A Piha-Paul; Apostolia M Tsimberidou; Siqing Fu; Ralph Zinner; Filip Janku; Yunfang Jiang; Mei Huang; Kristin L Parkhurst; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2014-10-18       Impact factor: 3.850

4.  Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Authors:  Valentine M Macaulay; Mark R Middleton; S Gail Eckhardt; Charles M Rudin; Rosalyn A Juergens; Richard Gedrich; Sven Gogov; Sean McCarthy; Srinivasu Poondru; Andrew W Stephens; Shirish M Gadgeel
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531

5.  The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop.

Authors:  Mariana Maschietto; Jocelyn Charlton; Daniela Perotti; Paolo Radice; James I Geller; Kathy Pritchard-Jones; Mark Weeks
Journal:  Oncotarget       Date:  2014-09-30

6.  Asparaginyl endopeptidase promotes the invasion and metastasis of gastric cancer through modulating epithelial-to-mesenchymal transition and analysis of their phosphorylation signaling pathways.

Authors:  Yuehong Cui; Yan Wang; Hong Li; Qian Li; Yiyi Yu; Xiaojing Xu; Bei Xu; Tianshu Liu
Journal:  Oncotarget       Date:  2016-06-07

7.  Challenges and perspective of drug repurposing strategies in early phase clinical trials.

Authors:  Shumei Kato; Stacy L Moulder; Naoto T Ueno; Jennifer J Wheler; Funda Meric-Bernstam; Razelle Kurzrock; Filip Janku
Journal:  Oncoscience       Date:  2015-06-30

8.  IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma.

Authors:  Ling Gao; Xiaolong Wang; Xiaofei Wang; Linmei Zhang; Cui Qiang; Su'e Chang; Wenhao Ren; Shaoming Li; Yang Yang; Dongdong Tong; Cheng Chen; Zongfang Li; Tusheng Song; Keqian Zhi; Chen Huang
Journal:  Oncotarget       Date:  2014-05-15

9.  Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis.

Authors:  Isabel Heidegger; Johann Kern; Philipp Ofer; Helmut Klocker; Petra Massoner
Journal:  Oncotarget       Date:  2014-05-15

10.  Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy.

Authors:  Qinhao Wang; Yi Ru; Daixing Zhong; Jing Zhang; Libo Yao; Xia Li
Journal:  Oncotarget       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.